RxDoctor Payments Data

Jeffrey Voreis, MD

Internal Medicine · Georgiana, ALNPI 1144239450

Payments from drug & device makers

$896in general payments, 2019–2025

Across 61 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$487
  • Pfizer$104
  • AbbVie$62
  • Bayer$46
  • Mylan Specialty L.p.$45
  • Novartis$40
  • plus $113 from 5 others

What the payments were for

  • Food & beverage$896100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$896 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$40,400
Medicare patients
209
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$28,228
TrulicityDulaglutide12$24,457
EliquisApixaban40$22,749
JardianceEmpagliflozin32$22,006
RexultiBrexpiprazole27$19,183
NuedextaDextromethorphan Hbr/Quinidine11$16,415
Tresiba Flextouch U-200Insulin Degludec11$16,292
Breo ElliptaFluticasone/Vilanterol24$11,690
XareltoRivaroxaban23$10,043
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen365$7,927
EntrestoSacubitril/Valsartan15$7,038
Pregabalin155$4,357
Gabapentin362$4,323
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$3,826
Sucralfate29$2,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$487$28,22830 claims
PfizerEliquis$104$22,74940 claims
Otsuka America Pharmaceutical, Inc.Rexulti$19$19,18327 claims
Johnson & JohnsonXarelto$22$10,04323 claims
NovartisEntresto$40$7,03815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Georgiana

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →